A Retrospective Chart Review Study of Gene-Eden-VIR/Novirin

April 24, 2016 updated by: The Center for the Biology of Chronic Disease
This study measured the changes in health-related complaints by analyzing charts of individuals, who are infected with a latent virus, who have used Gene-Eden-VIR/Novirin.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

The medical community calls the movement from severe to mild disease and from mild to normal health, 'relieving symptoms', and the interventions that cause such movement, drugs, medications, or therapies. The alternative community calls the movement from normal health to superior health, 'boosting health' (or boosting the immune system, or improving your sex drive, or boosting any another well functioning physiological system), and the interventions that cause such movement, natural remedies, dietary supplements, complementary treatments, etc. In general, these interventions aim to achieve superior performance of a normal human body. Of course, boosting the body's normal performance improves many of its capabilities, such as higher resistance to diseases, faster recovery from fatigue, better mental concentration, etc. Each movement presents different objectives. Relieving symptoms represents the ability of an intervention to reduce the frequency, duration, and severity of a disease. In contrast, boosting health represents the ability of an intervention to increase the frequency, duration, and quality of a person's health. In the current study, the investigators would like to measure the changes in health-related complaints by analyzing charts of individuals, who are infected with latent virus, and who have used Gene-Eden-VIR/Novirin.

Study Type

Observational

Enrollment (Actual)

1000

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • United States
    • New York
      • Valley Cottage, New York, United States, 10989
        • The Center for the Biology of Chronic Disease

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Probability Sample

Study Population

Men and women ages greater than 18 years old

Description

Inclusion Criteria:

  • Latent viral infection with either HSV, HPV, VZV, EBV, or CMV
  • Taking Gene-Eden-VIR/Novirin

Exclusion Criteria:

  • Use of other antiviral treatments

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: Cohort
  • Time Perspectives: Retrospective

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Herpes Simplex Virus Infection
Gene-Eden-VIR/Novirin, oral, 1-4 capsules per day, 12 months
Dietary supplement: Gene-Eden-VIR/Novirin
Human Papillomavirus Infection
Gene-Eden-VIR/Novirin, oral, 1-4 capsules per day, 12 months
Dietary supplement: Gene-Eden-VIR/Novirin
Epstein-Barr Virus Infection
Gene-Eden-VIR/Novirin, oral, 1-4 capsules per day, 12 months
Dietary supplement: Gene-Eden-VIR/Novirin
Cytomegalovirus Infection
Gene-Eden-VIR/Novirin, oral, 1-4 capsules per day, 12 months
Dietary supplement: Gene-Eden-VIR/Novirin
Varicella Zoster Virus Infection
Gene-Eden-VIR/Novirin, oral, 1-4 capsules per day, 12 months
Dietary supplement: Gene-Eden-VIR/Novirin

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
frequency of symptoms
Time Frame: one year
one year
duration of symptoms
Time Frame: one year
one year

Secondary Outcome Measures

Outcome Measure
Time Frame
time to first recurrence
Time Frame: one year
one year

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

The Center for the Biology of Chronic Disease

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

January 1, 2016

Primary Completion (Actual)

March 1, 2016

Study Completion (Actual)

March 1, 2016

Study Registration Dates

First Submitted

March 17, 2016

First Submitted That Met QC Criteria

March 21, 2016

First Posted (Estimate)

March 22, 2016

Study Record Updates

Last Update Posted (Estimate)

April 26, 2016

Last Update Submitted That Met QC Criteria

April 24, 2016

Last Verified

April 1, 2016

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 022015

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

Undecided

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Epstein-Barr Virus Infections

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Brazil

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe